OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:261559
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome (Orphanet code 261559) is an obsolete disease entry that was previously used to describe cases of blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) attributed specifically to chromosomal rearrangements involving the 3q23 region. BPES is a developmental condition primarily affecting the eyelids and surrounding structures, characterized by four major features: blepharophimosis (narrowing of the horizontal eye opening), epicanthus inversus (a skin fold arising from the lower eyelid), ptosis (drooping of the upper eyelids), and telecanthus (increased distance between the inner corners of the eyes). These features are typically present from birth and can impair vision if left untreated. This specific entry has been marked as obsolete in Orphanet, meaning it has been retired and its cases are now classified under the broader BPES entity (Orphanet code 126), which is most commonly caused by mutations or rearrangements involving the FOXL2 gene located at chromosome 3q22.3-q23. BPES is inherited in an autosomal dominant pattern and is subdivided into two types: Type I, which includes premature ovarian insufficiency in females, and Type II, which involves only the eyelid malformations. Management typically involves surgical correction of the ptosis and blepharophimosis, usually performed in early childhood to optimize visual development and prevent amblyopia. Patients with Type I BPES may also require reproductive counseling and hormonal management for ovarian insufficiency.

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome.

View clinical trials →

No actively recruiting trials found for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome community →

No specialists are currently listed for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndromeForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome.

Start the conversation →

Latest news about OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome

No recent news articles for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome

What is OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome?

Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome (Orphanet code 261559) is an obsolete disease entry that was previously used to describe cases of blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) attributed specifically to chromosomal rearrangements involving the 3q23 region. BPES is a developmental condition primarily affecting the eyelids and surrounding structures, characterized by four major features: blepharophimosis (narrowing of the horizontal eye opening), epicanthus inversus (a skin fold arising from the lower eyelid), ptosis (drooping of the u

How is OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome inherited?

OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome typically begin?

Typical onset of OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to 3q23 rearrangement syndrome is neonatal. Age of onset can vary across affected individuals.